Skip to main content

WuXi AppTec

WuXi AppTec Co Ltd is a China-based contract research, development, and manufacturing organization (CRDMO) serving the global pharmaceutical and biotechnology industries. The company operates an end-to-end service platform covering small molecule drug discovery, chemical synthesis, testing, advanced analytics, and manufacturing. Its operations are structured into five core business segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU (cell and gene therapy), and WuXi DDSU. Revenue is principally generated from fee-for-service research agreements and commercial manufacturing contracts with healthcare developers. Primary end markets comprise multinational pharmaceutical corporations, emerging biotechnology firms, and medical research institutes across North America, Europe, and Asia-Pacific. WuXi AppTec holds a dominant global market position in outsourced pharmaceutical R&D services and contract manufacturing. The company is headquartered in Shanghai, China, and maintains dual listings on the Shanghai Stock Exchange and the Stock Exchange of Hong Kong under ticker symbol 603259.

40 of the funds FundTelligence covers report a position in WuXi AppTec.

Legal name
WuXi AppTec Co Ltd
Sector
Health Care
Country
China
Funds holding it
40

Funds holding WuXi AppTec

Showing the 8 largest of 40 funds holding it.

Loading...